Genetic Technologies Executes Non-Coding License Agreement With EraGen Biosciences

The license granted by GTG covers the activities of EraGen in relation to its genetic diagnostic and analysis products, limited to US and Canada.

Although not a counterparty to GTG’s US patent infringement suit, discussions between GTG and EraGen regarding GTG’s non-coding patents have been proceeding for some time, and have now resulted in GTG granting to EraGen a non-exclusive license for all EraGen products, as well as the normalisation of past historical sales by EraGen.

The commercial terms of the license granted to EraGen are subject to confidentiality between the parties.

GTG is a genetic testing and reproductive services business which, together with an international patents and allied research activities, aims at uncovering the impact of DNA on health.

EraGen is a company provides clinical laboratories and medical researchers with the next generation of easy-to-use molecular assays for the early detection and monitoring of diseases, based in Madison, Wisconsin, US.